Immunotherapy for Bladder Cancer
Drs. Finkelstein and Pieczonka review new intravesical immunotherapies for bladder cancer, challenges in practice, and future potential of radiation combinations.
Read More
Select Page
Christopher Pieczonka, MD, is the Chief Executive Officer for Associated Medical Professionals, and Director of Clinical Research at U.S. Urology Partners in Syracuse, New York. Dr. Pieczonka specializes in advanced prostate and bladder cancer.
Dr. Pieczonka earned his Bachelor of Arts in Biology at Canisius University in Buffalo, New York. He received his medical degree and completed his surgical and urologic training at the University of Buffalo in New York.
Dr. Pieczonka has served as the Executive Vice-President of the Physician Teamster Alliance of Central New York Local #1149. He has been the primary investigator of over 50 interventional oncology studies, and is currently managing over 40 clinical studies in Phases 1-3. He is an active member of the American Urological Association, American Society of Clinical Oncology, and the Society of Urologic Oncology. Dr. Pieczonka also has been co-author of over 100 publications and published abstracts. He was also designated as a UroLift® Center of Excellence physician.
Drs. Finkelstein and Pieczonka review new intravesical immunotherapies for bladder cancer, challenges in practice, and future potential of radiation combinations.
Read More